Giulia Pellizzari
A5010500551- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- Mast cells and histamine
- Cancer Immunotherapy and Biomarkers
- Phagocytosis and Immune Regulation
- Immune Cell Function and Interaction
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Chemokine receptors and signaling
- Food Allergy and Anaphylaxis Research
- Advanced Breast Cancer Therapies
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- Radiopharmaceutical Chemistry and Applications
- T-cell and B-cell Immunology
- Asthma and respiratory diseases
- Peptidase Inhibition and Analysis
- Diabetes and associated disorders
- Epigenetics and DNA Methylation
- Immunodeficiency and Autoimmune Disorders
- Allergic Rhinitis and Sensitization
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- CAR-T cell therapy research
- Platelet Disorders and Treatments
- Glutathione Transferases and Polymorphisms
King's College London
2016-2025
Guy's Hospital
2016-2025
University College London
2021-2023
CRUK Lung Cancer Centre of Excellence
2023
St Thomas' Hospital
2016-2018
University of Trieste
2015
Abstract Outcomes for half of patients with melanoma remain poor despite standard-of-care checkpoint inhibitor therapies. The prevalence the melanoma-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4) expression is ~70%, therefore effective immunotherapies directed at CSPG4 could benefit many patients. Since IgE exerts potent immune-activating functions in tissues, we engineer a monoclonal antibody human constant domains recognizing to target melanoma. binds melanomas including...
Abstract Purpose: Highly aggressive triple-negative breast cancers (TNBCs) lack validated therapeutic targets and have high risk of metastatic disease. Folate receptor alpha (FRα) is a central mediator cell growth regulation that could serve as an important target for cancer therapy. Experimental Design: We evaluated FRα expression in by genomic (n = 3,414) IHC 323) analyses its association with clinical parameters outcomes. measured the functional contributions TNBC biology RNA interference...
IgE antibodies are key mediators of antiparasitic immune responses, but their potential for cancer treatment via antibody-dependent cell-mediated cytotoxicity (ADCC) has been little studied. Recently, tumor antigen-specific IgEs were reported to restrict cell growth by engaging high-affinity Fc receptors on monocytes and macrophages; however, the underlying therapeutic mechanisms undefined
Abstract All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers potential enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with primary objective exploring safety and tolerability MOv18 chimeric first-in-class IgE antibody, in patients tumours expressing relevant antigen, folate receptor-alpha. The incorporated skin prick basophil activation tests (BAT) to select at...
Basophils are involved in manifestations of hypersensitivity, however, the current understanding their propensity for activation and prognostic value cancer patients remains unclear. As healthy atopic individuals, basophil populations were identified blood from ovarian (n = 53) with diverse tumor histologies treatment histories. Ex vivo was measured by CD63 expression using test (BAT). Irrespective prior treatment, basophils could be activated stimulation IgE- (anti-FcεRI anti-IgE) non-IgE...
B cells are known to contribute the anti-tumor immune response, especially in immunogenic tumors such as melanoma, yet humoral immunity has not been characterized these cancers detail. Here we show comprehensive phenotyping samples of circulating and tumor-resident well serum antibodies melanoma patients. Memory enriched compared blood paired feature distinct antibody repertoires, linked specific isotypes. Tumor-associated undergo clonal expansion, class switch recombination, somatic...
Cancer immunotherapy with monoclonal antibodies and chimeric antigen receptor (CAR) T cell therapies can benefit from selection of new targets high levels tumor specificity early assessments efficacy safety to derisk potential therapies. Employing mass spectrometry, bioinformatics, immuno-mass spectrometry CRISPR/Cas9 we identified the target tumor-specific SF-25 antibody. We engineered IgE CAR immunotherapies derived clone evaluated for cancer therapy. as tumor-associated SLC3A2, a surface...
IgE monoclonal antibodies hold great potential for cancer therapy. Preclinical in vivo systems, particularly those which the antibody recognizes host species target antigen and binds to cognate Fc receptors, are often closest approximation human exposure represent a key challenge evaluating safety of antibody-based therapies. We sought develop an immunocompetent rat system assess rodent anti-tumor IgE, as surrogate therapeutic candidate. generated against tumor-associated chondroitin sulfate...
Abstract Background: All antibodies approved for the treatment of cancer are monoclonal IgGs, and no IgE therapy has yet been tested in humans. The biology IgE, compared with IgG, offers potential enhanced immune surveillance superior effector cell potency against tumor cells. preclinical models not associated allergic toxicity even immunocompetent animals, vivo efficacy compares favorably equivalent IgGs. Methods: We conducted a first-in-human first-in-class trial MOv18, chimeric patients...
Azathioprine (AZA), 6-mercaptopurine (6-MP), and 6-thioguanine (6-TG) are antimetabolite drugs, widely used as immunosuppressants anticancer agents. Despite their proven efficacy, a high incidence of toxic effects in patients during standard-dose therapy is recorded. The aim this study to explain, from mechanistic point view, the clinical evidence showing significant role glutathione-S-transferase (GST)-M1 genotype on AZA toxicity inflammatory bowel disease patients. To aim, human nontumor...
Abstract Background: Responses to checkpoint inhibitor (CPI) monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) have been limited. This is likely due a “cold” tumour immune microenvironment. We hypothesised that mCRPC will be more respond if they positive immunogenic signature (ImS+). report the response/safety for NIVO + IPI pts ImS+ from cohort 1 of NEPTUNES study. Methods: Pts who progressed following ≥1 line therapy and were eligible. was defined by...